Transfusion safety monitoring and learning provide a mechanism for identifying transfusion risks, enabling medical institutions to implement intervention measures, to reduce transfusion risks, and ultimately to improve patient safety. Recently, in response to ongoing challenges in transfusion safety, the UK Serious Hazards of Transfusion (SHOT) integrated and transformed the recommendations scattered in previous annual reports, and released the Standards for Transfusion Safety. This document specifies standards and requirements/criterion in eight key areas, including transfusion safety, transfusion information technology and equipment, supporting staff to work safely, staff education and training, safety culture, patients as safety partners, haemovigilance and risk management, and governance. The issue and implementation of the Standards marks a significant transformation in the UK's blood transfusion safety governance strategy. Understanding the content and background of the Standards will be beneficial for contemplating and exploring the future direction of China's blood transfusion safety governance strategy.

As the second part of this series, this article summarizes and synthesizes the key aspects of UK Serious Hazards of Transfusion (SHOT), SHOT’s continuous promotion of learning from excellent daily transfusion events over the past six years. This summary is based on an introduction to the holistic approach to improving patient safety—proactively learning from both failures and successes. The covered topics include an overview, definitions, case studies, implementation methods, safety culture, psychological safety in the workplace, civility in work, the use of neutral language, leading and lagging indicators, and compassionate governance. It is hoped that this article will assist domestic colleagues in understanding and studying the strategic significance of the transformation of transfusion safety governance in the UK, and inspire reflection on the strategic development direction of transfusion safety governance in China.

Whole blood, containing all blood components in physiological proportions, is a preferred resuscitative fluid for patients with severe hemorrhage. The preparation, supply, and clinical use of whole blood are more convenient, safe, and effective, offering the advantages of reduced blood utilization and associated costs. In recent years, an increasing number of countries and regions have initiated whole blood transfusion programs. The newly issued "Medical Treatment Specifications for Trauma Patients in Emergencies (2025 Edition)" by China's National Health Commission designates whole blood as the preferred choice for early trauma transfusion. Establishing a priority supply mechanism for whole blood has become a critical task for blood services in China. This paper introduces the recommendations of the European Blood Alliance practical guidance on implementation of a whole blood programme within a blood service, hoping to provide insights and assistance in establishing a priority supply mechanism for whole blood in China.

This article reviews the history and current status of the development of quality management good practice for blood establishments worldwide, covering its standardization, systematization, formalization, and global harmonization and collaboration. It introduces three international harmonization guidelines for quality management in blood establishments, namely, the WHO Good practices for blood establishments, the EU Good practice guidelines for blood establishments, and the PIC/S Good practices guide for blood establishments and hospital blood banks, with the aim of contributing to the reflection and exploration of directions for revising quality management standards for blood establishments in China.

The recently updated best practice guidelines for hospital blood inventory management by the UK Blood Stocks Management Scheme comprehensively address best practices for managing blood component inventory in hospital transfusion laboratories. These include training and responsibility of laboratory staff, appropriate stock levels and ordering patterns, promoting best practice, patient blood management, movement of stock, satellite fridges and remote issue, useful data tools, KPIs and benchmarking, effective collaboration, blood management planning and conservation, and managing stocks during an IT downtime. This article introduces the main content of the guidelines, aiming to provide insights and support for the development, implementation, and continuous improvement of blood inventory management standards in Chinese hospitals.

Diabetic macular ischemia(DMI), playing key roles behind the progression of diabetic retinopathy(DR), is one of the causes of vision loss. Its pathophysiological process is complex, involving vascular structure changes, hemodynamic abnormalities, and many other aspects. Traditional inspection methods often make it difficult to accurately capture subtle changes in DMI. In turn, optical coherence tomography angiography(OCTA)has opened a pathway to the diagnosis and treatment of DMI, which not only has the advantages of non-invasive, safe and rapid imaging, but also furnishes high-resolution retinal vascular images to provide qualitative and quantitative descriptions of DMI. OCTA can visually show the morphological and structural changes of blood vessels in the macular region, as well as reveal the characteristics of pathological changes in the superficial and deep capillary plexus of DMI patients, which provides a deeper understanding of DMI and a new treatment option of diabetic eye disease.

Objective:To construct an infectious clone of a Chinese HIV-1 CRF01_AE epidemic strain with strong replication capacity，and comprehensively identify its viral phenotype and replication capacity.Methods:Using the CRF01_AE clinical isolate GX2005002，which was previously isolated from whole blood of an HIV-1-infected individual in China by our laboratory，as the parental strain，the full-length genome of the virus（9.7 kb）was divided into 5' half fragment（5.1 kb）and 3' half fragment（4.6 kb）for amplification. The proviral DNA was used as a template to amplify the virus genome，which was then ligated into the eukaryotic expression vector pEASY-T1. The consistency of its sequence with the parental strain sequence was identified through full-length genome sequencing and phylogenetic analysis. The replication capacity，syncytium inducibility，and cell tropism were experimentally identified to determine its phenotypic consistency with the parental strain.Results:An infectious clone of the CRF01_AE strain was successfully constructed，and its genome sequence exhibited high consistency with the sequence of the parental strain. By transfecting target cells，a derivative virus with infectious activity and replication capability was successfully rescued. The derived virus maintained phenotypic characteristics consistent with the parental strain，such as cell tropism and syncytium inducibility.Conclusion:This study successfully constructed an infectious clone of a Chinese HIV-1 CRF01_AE epidemic strain with clear background and distinct phenotype. The genomic sequence and viral phenotypic characteristics of the derived virus are basically consistent with the parental strain，providing strong representation of the original isolate and serving as a powerful tool for research on the correlation between the genetic characteristics，viral phenotype，and pathogenicity of HIV-1 CRF01_AE strains.

Objective:To develop an artificial intelligence (AI)-based platelet review strategy to identify abnormal platelet histograms with no significant difference between initial impedance platelet count (PLT-I) and PLT-F results.Methods:This study included 5 119 routine blood analysis in Nanfang Hospital of Southern Medical University and its Ganzhou branch from July 2023 and March 2024. Specimens exhibiting abnormal platelet histograms and an initial platelet count >40×10?/L underwent review using the fluorescent platelet count (PLT-F) channel. Consistency of the results was defined as a difference between impedance platelet count (PLT-I) and PLT-F less than ±20% of the PLT-F results. A deep learning model was developed using platelet and red blood cell histogram data from a training set of 3 807 specimens. The model′s diagnostic performance was evaluated on an independent external validation set ( n=805) using receiver operating characteristic (ROC) curve analysis. Changes in the number of reviewed samples and sample turnaround time were analyzed to assess its clinical utility. Results:The deep learning model based on platelet and red blood cell histograms achieved an area under the ROC curve (AUC) of 0.854 in the training set. At a cutoff value of 0.1, the sensitivity was 0.954 and specificity was 0.358. The model could reduce review by 16.80% (190/1 131). In the validation set, the AUC was 0.805, with a sensitivity of 0.955 and specificity of 0.307, corresponding to a reduction of 17.41% (47/270) in reviewed specimens.Conclusion:The platelet review prediction model developed based on deep learning technology can efficiently identify samples with consistent results before and after review, reducing unnecessary reviews and shortening specimen testing time, thereby improving the efficiency of platelet test.

Objectives:To explore the predictive value of residual Murray's law-based quantitative flow ratio(μQFR)on long-term vessel-oriented composite endpoints(VoCE).Methods:This retrospective study included 3 510 patients from the FAVOR Ⅲ China trial.Offline residual μQFR analysis was performed on all vessels(diameter≥2.5 mm)with 50%-90%stenotic lesions.Patients were stratified into high-,intermediate-,and low-risk groups based on residual μQFR tertiles.The primary endpoint was 3-year VoCE,defined as a composite of cardiac death related to the target vessel,target vessel-related spontaneous myocardial infarction,and ischemia-driven target vessel revascularization.Results:Offline analysis was performed on 5 256 vessels from 3 510 patients.The mean residual μQFR was 0.92±0.75.The high-risk group(residual μQFR≤0.91)with 1 554 patients(1 958 vessels);the intermediate-risk group(residual μQFR 0.92-0.96)with 1 211 patients(1 906 vessels);and the low-risk group(residual μQFR>0.96)with 745 patients(1 392 vessels).Over 3-year follow-up,VoCE occurred in 227 vessels(4.3%).The 3-year VoCE incidence was significantly higher in the high-risk group compared to the intermediate-and low-risk groups(6.2%vs.4.1%vs.2.5%,log-rank P<0.001),primarily driven by ischemia-driven target vessel revascularization(5.0%vs.3.0%vs.1.6%,log-rank P<0.001).Hypertension(OR=0.83,95%CI:0.72-0.96),hypercholesterolemia(OR=0.84,95%CI:0.73-0.97),bifurcation lesions(OR=0.72,95%CI:0.63-0.83),moderate/severe calcification(OR=0.70,95%CI:0.57-0.84),and tandem lesions(OR=0.59,95%CI:0.47-0.75)were independent predictors of lower residual μQFR values.Conclusions:Lower residual μQFR is significantly associated with increased VoCE risk during the 3-year follow up period.

This review systematically describes the application of artificial intelligence in the comprehensive management of patients with valvular heart disease(VHD).In population screening,technologies such as artificial intelligence(AI)electrocardiogram(AI-ECG),AI auscultation,and new imaging modalities play important roles,help early detection of VHD.In imaging assessment and diagnosis,AI can add automatic morphological and functional evaluations,assisting in precise typing and risk prediction to accurately determine the timing of VHD intervention.For treatment,especially transcatheter aortic valve replacement(TAVR),AI can assist in image analysis and strategy formulation in a variety of ways throughout the process,improving procedure success rates and avoiding complications.Although the application of AI is limited by factors such as data quality and computational capacity,in the future,multi-center cooperation can be adopted to expand data samples and enhance computational capabilities to improve AI performance,thus further optimizing VHD management.